A comparative study of bone remodeling molecules expression in different types of jaw ameloblastoma

Iakovou, Maria; Chrysomali, Evanthia; Piperi, Evangelia; Fanourakis, Galinos; Sklavounou, Alexandra; Vlachodimitropoulos, Dimitrios; Tseleni‐Balafouta, Sofia

doi:10.1111/jop.12263

Cited by 4 publications

(8 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Studies of AM have demonstrated that many molecular processes are involved in tumor progression. These processes include proteins involved in cell adhesion [ 23 ], bony reconstruction, tumor front [ 24 , 25 ], apoptosis regulation, cell cycle/cell proliferation [ 2 , 26 , 27 ], and epidermal growth factor gene and BRAF V600 E mutations [ 28 ].…”

Section: Discussionmentioning

confidence: 99%

Immunoexpression of Ki-67, MCM2, and MCM3 in Ameloblastoma and Ameloblastic Carcinoma and Their Correlations with Clinical and Histopathological Patterns

et al. 2015

View full text Add to dashboard Cite

Cell proliferation assays are performed using antibodies against nuclear proteins associated with DNA replication. These nuclear proteins have gained special interest to predict the biological and clinical behaviors of various tumors. The aim of this study was to analyze the presence of Ki-67 protein and the minichromosome maintenance-2 (MCM2) and maintenance-3 (MCM3) proteins in ameloblastoma. Materials and Methods. Cell proliferation marker expression levels were assessed via immunohistochemistry in 111 ameloblastoma cases (72 unicystic ameloblastoma samples, 38 solid/multicystic ameloblastoma samples, and 1 ameloblastic carcinoma). The label index was performed as described previously. Results. MCM2 and MCM3 showed higher proliferation indexes in all variants of ameloblastoma compared to the classic marker Ki-67. No correlation between the proliferation index and the clinical and protein expression data was observed. Conclusion. The results suggest that clinical features do not directly affect tumor cell proliferation. Moreover, the high levels of cellular proliferation of MCM2 and MCM3 compared with Ki-67 may indicate that MCM2 and MCM3 are more sensitive markers for predicting the growth rate and eventually might be helpful as a tool for predicting aggressive and recurrent behaviors in these tumors.

show abstract

Section: Discussionmentioning

confidence: 99%

Immunoexpression of Ki-67, MCM2, and MCM3 in Ameloblastoma and Ameloblastic Carcinoma and Their Correlations with Clinical and Histopathological Patterns

et al. 2015

View full text Add to dashboard Cite

show abstract

“…The immunohistochemical study of proteins associated with the cell cycle helps in the understanding of the biological behavior of certain neoplasms. 5 Growth and tumoral progression of ameloblastomas are related to diverse molecular processes, such as adhesion, 23 invasion, 24 growth factors, 25 apoptosis, 26 and cell proliferation, 19 among others.…”

Section: Discussionmentioning

confidence: 99%

Comparative Study of the Minichromosome Maintenance Proteins Complex (MCM 4/5/6) in Ameloblastoma and Unicystic Ameloblastoma

et al. 2018

View full text Add to dashboard Cite

show abstract

“…From the nine studies analyzed, only three (14,21,22) mentioned the ethical criteria involved. As for specimen fixation, five studies (13,14,21,23,25) used 10% formaldehyde and four studies (4,22,24,26) did not mention the means of fixation. All studies (4,13,14,21-26) used immunohistochemistry as the diagnostic method.…”

Section: Study Characteristicsmentioning

confidence: 99%

“…Four studies (13,14,22,23) used anti-OPG (N-20; Santa Cruz Biotechnology) and anti-RANKL (N-19; Santa Cruz Biotechnology) primary polyclonal antibodies from rabbits, while two studies (21,25) used anti-OPG (H-249, scll383, Santa Cruz Biotechnology) and anti-RANKL (FL-327, sc9073, Santa Cruz Biotechnology) primary polyclonal antibodies from rabbits. One study (24) used anti-OPG (clone ab73400 Abcam laboratories), anti-RANK (clone 64C1385 Abcam laboratories), and anti-RANKL (clone 12A668 Abcam laboratories) antibodies.…”

Section: Study Characteristicsmentioning

confidence: 99%

See 1 more Smart Citation

RANK, RANKL, and OPG in Dentigerous Cyst, Odontogenic Keratocyst, and Ameloblastoma: A Meta-Analysis

et al. 2021

View full text Add to dashboard Cite

The aim of this study was to assess and compare RANK, RANKL, and OPG immunoexpression in dentigerous cyst, odontogenic keratocyst, and ameloblastoma. The protocol was registered in PROSPERO (CRD42018105543). Seven databases (Embase, Lilacs, LIVIVO, PubMed, Scopus, SciELO, and Web of Science) were the primary search sources and two databases (Open Grey and Open Thesis) partially captured the “grey literature”. Only cross sectional studies were included. The JBI Checklist assessed the risk of bias. A meta-analysis with random effects model estimated the values from the OPG and RANKL ratio reported by the individual studies and respective 95% confidence intervals. The heterogeneity among studies was assessed with I2 statistics. Only nine studies met the inclusion criteria and were considered in the analyses. The studies were published from 2008 to 2018. Two studies presented low risk of bias, while seven studies presented moderate risk. The meta-analysis showed the highest OPG>RANKL ratio for dentigerous cyst (ES=43.3%; 95% CI=14.3-74.8) and odontogenic keratocyst (ES=36.8%; 95% CI=18.8-56.7). In contrast, the highest OPG<RANKL ratio was found for ameloblastoma (ES=73.4%; 95% CI=55.4-88.4) and it was higher in the stromal region compared to the odontogenic epithelial region. The results may explain the aggressive potential of ameloblastoma from the higher OPG<RANKL ratio in this tumor, while it was lower for dentigerous cyst and odontogenic keratocyst.

show abstract

A comparative study of bone remodeling molecules expression in different types of jaw ameloblastoma

Cited by 4 publications

References 36 publications

Immunoexpression of Ki-67, MCM2, and MCM3 in Ameloblastoma and Ameloblastic Carcinoma and Their Correlations with Clinical and Histopathological Patterns

Immunoexpression of Ki-67, MCM2, and MCM3 in Ameloblastoma and Ameloblastic Carcinoma and Their Correlations with Clinical and Histopathological Patterns

Comparative Study of the Minichromosome Maintenance Proteins Complex (MCM 4/5/6) in Ameloblastoma and Unicystic Ameloblastoma

RANK, RANKL, and OPG in Dentigerous Cyst, Odontogenic Keratocyst, and Ameloblastoma: A Meta-Analysis

Contact Info

Product

Resources

About